Sinopharm is showing a bullish pattern, with the EMA 20 positioned above the EMA 50. This alignment suggests that a gradual upward movement could follow. A breakout above HKD21 would confirm and strengthen this bullish outlook. The MACD bullish crossover reinforces the existing bullish trend.
Net profit is forecasted to increase at a 9% CAGR for the next three years, maintaining consistent net margins of 1.4% throughout the period
Source: Rakuten Research - 14 Nov 2024
To sign up for an account : http://bit.ly/40BNqKI
[Youtube Tutorial] Account Opening & Enable Foreign Equity:http://bit.ly/3I5Jzxo